 NEW YORK, Oct. 12, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH, a biopharmaceutical company, today announced that is has received Human Research Ethics Committee HREC clearance to commence cohort 2 of the Phase 1b clinical trial of BioLexa Lotion for the treatment of mild to moderate atopic dermatitis in Australia. BioLexa Trial Design: Randomized, double-blind, parallel-design, placebo-controlled study. 